BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord InjuryBusiness Wire • over 4 years ago---
- 'BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company
developing cellular therapies for unmet needs, announced today the issuance of a
Notice of Allowance for a patent from the United States Patent and Trademark Office
(USPTO) for United States Patent Application No. 15...'